Oxaliplatin-d<sub>10</sub>

Oxaliplatin-d10

CAT N°: 34408
Price:

1,449.00 1,231.65

Oxaliplatin-d10 is intended for use as an internal standard for the quantification of oxaliplatin (Item No. 13106) by GC- or LC-MS. Oxaliplatin is a platinum-containing DNA-crosslinking agent.{60566} It induces the formation of DNA inter- and intrastrand crosslinks and DNA-protein adducts, inhibits DNA and RNA synthesis, and induces apoptosis in cancer cells. Oxaliplatin is cytotoxic to cisplatin-sensitive A2780(1A9) and KB-3-1 cells and cisplatin-resistant A2780-E(80) and KB-CP20 cells (IC50s = 0.12, 0.39, 4.7, and 2.7 µM, respectively).{60567} It reduces tumor growth in an HCCLM3 mouse xenograft model when administered at doses of 5 or 10 mg/kg once per week.{60568} Formulations containing oxaliplatin have been used in the treatment of advanced colorectal cancer and as adjuvants in stage III colon cancer.

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • (SP-4-2)-[(1R,2R)-1,2-cyclohexane-1,2,3,3,4,4,5,5,6,6-d10-diamine-?N1,?N2][ethanedioato(2-)-?O1,?O2]-platinum
  • Correlated keywords
    • deuterated deuterium GCMS LCMS A-2780 A27801A9 A2780-E80 A2780E80 KBCP20 KBCP-20 HCCLM-3 NSC-266046 RP-54780 NSC266046 RP54780
  • Product Overview:
    Oxaliplatin-d10 is intended for use as an internal standard for the quantification of oxaliplatin (Item No. 13106) by GC- or LC-MS. Oxaliplatin is a platinum-containing DNA-crosslinking agent.{60566} It induces the formation of DNA inter- and intrastrand crosslinks and DNA-protein adducts, inhibits DNA and RNA synthesis, and induces apoptosis in cancer cells. Oxaliplatin is cytotoxic to cisplatin-sensitive A2780(1A9) and KB-3-1 cells and cisplatin-resistant A2780-E(80) and KB-CP20 cells (IC50s = 0.12, 0.39, 4.7, and 2.7 µM, respectively).{60567} It reduces tumor growth in an HCCLM3 mouse xenograft model when administered at doses of 5 or 10 mg/kg once per week.{60568} Formulations containing oxaliplatin have been used in the treatment of advanced colorectal cancer and as adjuvants in stage III colon cancer.

We also advise you